A Phase 1 Study of the Safety and Pharmacokinetics of AGS-16M18 in Subjects With Advanced Renal Cell Cancer

Summary

This is a first in human study of AGS-16M18 given every week to subjects with advanced renal cell cancer. AGS-16M18 will be administered as a 60 minute IV infusion on consecutive days until the disease worsens.

Timeline

Start

2008-10

Primary completion

2010-04

Completion

2010-04

Outcome

Outcome not reported

Stopped: “Trial was terminated due to the need to re-formulate the study drug.”

Drugs

Indications